Doxycycline attenuates l-DOPA-induced dyskinesia through an anti-inflammatory effect in a hemiparkinsonian mouse model - Archive ouverte HAL Access content directly
Journal Articles Frontiers in Pharmacology Year : 2022

Doxycycline attenuates l-DOPA-induced dyskinesia through an anti-inflammatory effect in a hemiparkinsonian mouse model

(1) , , , (2) , (2, 3) , (1)
1
2
3

Abstract

The pharmacological manipulation of neuroinflammation appears to be a promising strategy to alleviate l -DOPA-induced dyskinesia (LID) in Parkinson’s disease (PD). Doxycycline (Doxy), a semisynthetic brain-penetrant tetracycline antibiotic having interesting anti-inflammatory properties, we addressed the possibility that this compound could resolve LID in l -DOPA-treated C57BL/6 mice presenting either moderate or intermediate lesions of the mesostriatal dopaminergic pathway generated by intrastriatal injections of 6-OHDA. Doxy, when given subcutaneously before l -DOPA at doses of 20 mg kg −1 and 40 mg kg −1 , led to significant LID reduction in mice with moderate and intermediate dopaminergic lesions, respectively. Importantly, Doxy did not reduce locomotor activity improved by l -DOPA. To address the molecular mechanism of Doxy, we sacrificed mice with mild lesions 1) to perform the immunodetection of tyrosine hydroxylase (TH) and Fos-B and 2) to evaluate a panel of inflammation markers in the striatum, such as cyclooxygenase-2 and its downstream product Prostaglandin E2 along with the cytokines TNF-α, IL-1β and IL-6. TH-immunodetection revealed that vehicle and Doxy-treated mice had similar striatal lesions, excluding that LID improvement by Doxy could result from neurorestorative effects. Importantly, LID inhibition by Doxy was associated with decreased Fos-B and COX-2 expression and reduced levels of PGE 2 , TNF-α, and IL-1β in the dorsolateral striatum of dyskinetic mice. We conclude 1) that Doxy has the potential to prevent LID regardless of the intensity of dopaminergic lesioning and 2) that the anti-inflammatory effects of Doxy probably account for LID attenuation. Overall, the present results further indicate that Doxy might represent an attractive and alternative treatment for LID in PD.
Fichier principal
Vignette du fichier
fphar-13-1045465.pdf (1.69 Mo) Télécharger le fichier
Origin : Publisher files allowed on an open archive

Dates and versions

hal-03873142 , version 1 (26-11-2022)

Identifiers

Cite

Maurício dos Santos Pereira, Glauce Crivelaro Do Nascimento, Mariza Bortolanza, Patrick Pierre Michel, Rita Raisman-Vozari, et al.. Doxycycline attenuates l-DOPA-induced dyskinesia through an anti-inflammatory effect in a hemiparkinsonian mouse model. Frontiers in Pharmacology, 2022, 13, ⟨10.3389/fphar.2022.1045465⟩. ⟨hal-03873142⟩
0 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More